PRESS RELEASE: Aquarius Population Health wins a prestigious SBRI grant from Innovate UK

Work has begun to develop a digital value proposition tool for a novel rapid sexually transmitted infection (STI) test

London, UK, 14 August 2017

Aquarius Population Health, a leading independent health economics consultancy, has recently been awarded an 18-month Innovate UK grant in collaboration with Atlas Genetics Ltd and the Applied Diagnostic Research and Evaluation Unit at St George’s University of London (total £2,000,000). The funding will be used to develop evidence for health services to support the introduction of a new rapid diagnostic test. In 30-minutes the test can diagnose multiple sexually transmitted infections including chlamydia and gonorrhoea – infections which could take up to a week to diagnose using the current laboratory testing systems.

Continue reading

Evaluating the use AMR POCT in treatment of gonorrhoea

Aquarius Population Health recently worked with the Applied Diagnostic Research & Evaluation Unit (ADREU) at St. Georges, University of London, to assess the cost-effectiveness of six hypothetical strategies for using antimicrobial resistance point-of-care testing to guide the treatment of gonorrhoea.  Our findings were presented at the STI & HIV World Congress in Rio de Janeiro, Brazil. [Wednesday 12th July, Session 15: STI/HIV testing and management].

Continue reading

Evaluating multi-bug point-of-care tests for sexually transmitted infections

We were a collaborator on a recent Innovate UK-funded SBRI project with Atlas Genetics and the Applied Diagnostic Research and Evaluation Unit at St George’s University of London. In this project, our team compared the overall costs, patient benefits and cost-effectiveness of three different multi-pathogen point-of-care testing strategies with the current strategy of microscopy and lab-based testing.

This work was presented at the STI and HIV World Congress which takes place July 9-12 in Rio de Janeiro. The poster can be seen here.

Continue reading

Antimicrobial resistance point-of-care test for gonorrhoea

In a study commissioned by the Review on Antimicrobial Resistance, Aquarius Population Health worked with modellers at the University of Bristol to create a mathematical model. The model was used to assess the economic implications and treatment impact of introducing a hypothetical antimicrobial resistance (AMR) point-of-care test (POCT) for gonorrhoea. Results of the study were published this week in BMJ Open.

Continue reading

Antimicrobial resistance: Why it matters

Antimicrobial resistance (AMR) has been described as one of the world’s greatest threats to human and animal health. Some reports suggest that by 2050, AMR could kill around 10 million people each year worldwide.  Public health leaders warn we could enter a ‘post-antibiotic’ era where easily treatable common infections become untreatable.
Continue reading

Antimicrobial Resistance: Innovation in rapid diagnostics

Part 3: What role does innovation such as rapid diagnostics have in preventing AMR?

Just as new technology has helped us in the fight against global warming (fuel efficiency, clean energy etc.), technology can also help us in the fight against antimicrobial resistance (AMR). One such area is rapid diagnostics – identified as a key intervention for reducing AMR in the government’s 2016 Review of Antimicrobial Resistance.

Continue reading

Point of care testing: Disruptive innovation – is the NHS ready for it yet?

Elisabeth AdamsOur Managing Director, Elisabeth Adams, spoke in November about the importance of exploring the health economics of point of care testing (POCT) at the Royal Society of Medicine Telemedicine and eHealth event in London. The video of her presentation is now online – view the full talk here.

Why is it important to explore the health economics of point of care testing (POCT)?

Evaluating the health economics of POCTs can help us better understand the cost, benefits and value of implementing these tests, compared to standard laboratory tests. We need to explore the acquisition costs of innovative technology like POCTs compared to standard tests, as well as the benefits generated for patients, service providers, clinicians and public health in general. Benefits can include faster results, better care, fewer complications, more efficient services and better use of resources, and knock-on benefits like reduced prevalence of disease. Those making purchasing decisions for new tests need evidence to prove the value of the tests.

Continue reading

Understanding barriers to implementing point-of-care tests in paediatric patients

The team at Aquarius Population Health investigated the experience of implementing point-of-care tests (POCTs) for paediatric patients during respiratory disease season (winter 2014 – spring 2015), in collaboration with colleagues from three large hospitals in South London (Guy’s and St. Thomas’, King’s College Hospital, and St. George’s University Hospital). Each centre independently evaluated one POCT test (Enigma® MiniLab™ FluAB-RSV PCR assay, BioMérieux BioFire Filmarray, and Luminex RVP Fast v2) on paediatric patients either in the Accident and Emergency department or admitted as an inpatient.

Continue reading

Rapid on-demand testing of HPV and cervical cancer prevention: IPV Conference in Lisbon

Our managing director, Dr Elisabeth Adams, is presenting two posters at the 30th annual International Papillomavirus Conference  in Lisbon, Portugal.  The first poster, “Exploring the value of a rapid, on-demand test for the detection of human papillomavirus”, is a detailed look at the current patient pathways for cervical screening programmes, and key opinion leaders’ views on the impact a rapid diagnostic would have on the health and overall wellbeing of women.

Continue reading